SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

The Ohio State University Medical Center Acquires Mobetron from Intraop Medical, Inc.
[October 12, 2004]

The Ohio State University Medical Center Acquires Mobetron from Intraop Medical, Inc.

SANTA CLARA, Calif. --(Business Wire)-- Oct. 12, 2004 -- Intraop Medical, Inc. announced today that it had received an order for a Mobetron from the Arthur James Cancer Hospital at The Ohio State University Medical Center. The Mobetron will replace an intraoperative radiation therapy ("IORT") treatment system that has been in clinical use since the early 1990's. The Arthur James Cancer Hospital at the Ohio State University Medical Center has one of the world's premier IORT programs. They have conducted and published numerous clinical studies that integrate IORT in the treatment of cancer patients, including studies for patients with head and neck cancer, rectal cancer, gynecological cancer and pediatric cancers.



"Having a Mobetron installed at one of the world's recognized leading IORT centers is extremely gratifying," says Donald A. Goer, President & CEO of Intraop Medical, Inc. "This affords us the opportunity of expanding our customer base while continuing to work with premier research centers to develop new IORT protocols and applications. We are already working with the Arthur James Cancer Hospital and other centers on an IORT lung protocol (See accompanying news story). We look forward to strengthening our collaborations with IORT research centers throughout the world."

"The Mobetron will enable us to continue to provide electron beam IORT treatments for our patients," says Dr. Subir Nag, Director of Intraoperative Radiation Therapy and Brachytherapy at the Arthur James Cancer Hospital. "IORT is an important tool in our cancer treatment armamentarium. Because we can usually displace or protect normal tissues during the treatment, IORT allows us to increase the delivered dose to the patient substantially. For some patients with advanced disease this dose escalation may make the difference in controlling the tumor growth. We look forward to working with Intraop to continue to develop and expand IORT applications."


About Intraop Medical, Inc.

Intraop Medical, Inc. was formed in April 1993 to develop, manufacture, market and service the Mobetron, a mobile electron beam system designed for IORT treatment of cancer, coronary/vascular restenosis and other medical applications. Unlike other IORT systems, the Mobetron uses several patented technologies to allow IORT to be used without requiring shielding the operating room. The Mobetron can be moved between operating rooms or even between hospitals, thereby increasing the systems utilization and cost effectiveness.

About The Arthur James Cancer Hospital

The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University is one of only 38 National Cancer Institute-designated Comprehensive Cancer Centers in the United States and the only freestanding cancer hospital in the Midwest. Here specialists in every form of oncology are wholly committed to providing the highest level of cancer prevention, detection, treatment, education, and research, using different modalities to provide patients a multidisciplinary approach for cancer treatment. The cancer hospital has been performing IORT since the early 1990's.

About Intraop Medical Corporation

Intraop Medical, Inc. has entered into a Merger Agreement with Intraop Medical Corporation (OTCBB:IOPM), whereby Intraop Medical Corporation will acquire Intraop Medical, Inc. in a merger. Completion of the merger is subject to numerous conditions, including SEC approval. The shareholders of Intraop Medical, Inc. and the principal shareholder of Intraop Medical Corporation have already approved the merger. Intraop Medical Corporation, headquartered in Salt Lake City, Utah, currently has no operations or business.

This press release contains "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the company to execute its plans. By making these forward-looking statements, the company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

[ Back To TMCnet.com's Homepage ]







Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy